Lundbeck A/S's Lu AF28996 Parkinson's Data

Lundbeck A/S announced positive Phase 1b data for Lu AF28996, an investigational treatment for advanced Parkinson s disease, which will be presented at the 2026 AD/PD™ Conference. The trial evaluated safety, tolerability, pharmacokinetics, and early clinical signals, indicating that Lu AF28996 was generally well tolerated and showed signals consistent with its proposed mechanism of action, supporting continued clinical development. This novel compound, discovered by Lundbeck A/S, is designed to provide continuous dopaminergic stimulation to improve motor fluctuations and levodopa-induced dyskinesia. Additionally, Lundbeck A/S will present insights into Multiple system atrophy, a fatal neurodegenerative disease, highlighting advances in understanding disease progression and the amlenetug pivotal program, developed in collaboration with Genmab. These presentations underscore Lundbeck A/S's commitment to advancing innovative therapies for severe neurological conditions.